Whether it's a first-line chemotherapy, a small molecule inhibitor, a protein or genetic material, delivering that drug to the intended target and especially avoiding unintended off-target damage is key to a successful and satisfactory treatment.

​

Oligo Medic has developed a proprietary nanoparticle architecture combining active targeting and stealth to efficiently deliver a wide range of therapeutic payloads, drastically increasing the proportion of drug reaching the intended target.

​